Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 1 October 2021, including: the prospects for Merck & Co., Inc.’s Acceleron Pharma, Inc. acquisition; the pandemic and biotech capital in-flow; an interview with Menarini Group’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis AG's pharma president.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode: